Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest NASDAQ Biotechnology Index Stories

2013-08-15 08:28:44

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, August 15, 2013 /PRNewswire/ -- Today, Investors' Reports announced new research reports highlighting Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), Nektar Therapeutics (NASDAQ: NKTR), Sequenom Inc. (NASDAQ: SQNM), and Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK). Today's readers may access these reports free of charge - including full price...

2013-08-12 08:29:04

Editor Note: For more information about this release, please scroll to bottom NEW YORK, August 12, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), Exelixis, Inc. (NASDAQ: EXEL), Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), Puma Biotechnology, Inc. (NYSE: PBYI), and Halozyme Therapeutics, Inc. (NASDAQ: HALO). Today's readers may access these reports free of charge - including full price...

2013-08-08 08:30:46

Editor Note: For more information about this release, please scroll to bottom. LONDON, August 8, 2013 /PRNewswire/ -- On Wednesday, August 7, 2013, all three benchmark indexes closed lower, with the Dow Jones Industrial Average falling 0.31%, the S&P 500 falling 0.38%, and the NASDAQ declining 0.32%. Shares in healthcare companies also ended mostly lower. The major movers included Elan Corp. PLC (NYSE: ELN), Amarin Corp. PLC (NASDAQ: AMRN), Seattle Genetics Inc. (NASDAQ:...

2013-08-06 08:29:03

LONDON, August 6, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. On Monday, August 5, 2013, the S&P 500 closed 0.15% lower at 1,707.14. Shares in biotechnology companies ended on a mixed note as the broader market edged lower. The major movers in the sector included Gilead Sciences Inc. (NASDAQ: GILD), InterMune Inc. (NASDAQ: ITMN), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), and Halozyme Therapeutics Inc. (NASDAQ:...

2013-08-05 08:27:51

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, August 5, 2013 /PRNewswire/ -- Today, Investors' Reports announced new research reports highlighting Seattle Genetics Inc. (NASDAQ: SGEN), Santarus, Inc. (NASDAQ: SNTS), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), and PDL BioPharma, Inc. (NASDAQ: PDLI). Today's readers may access these reports free of charge - including full price targets,...

2013-07-16 08:26:26

NEW YORK, July 16, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Wall Street Reports announced new research reports highlighting Mylan Inc. (NASDAQ: MYL), Actavis, Inc. (NYSE: ACT), Warner Chilcott Plc (NASDAQ: WCRX), Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), and Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR). Today's readers may access these reports free of charge - including full price targets, industry...

2013-04-23 08:34:18

LONDON, April 23, 2013 /PRNewswire/ -- Following the expiration of patents on several blockbuster drugs, big pharma companies have been looking to boost their product pipeline. While in-house research and development will be crucial to boost product pipeline, major pharma companies may also benefit by collaborating with emerging biotechnology companies that have developed or are developing potential blockbuster drugs. Biotechnology stocks ended mostly lower on Monday even as...

2013-03-18 08:30:03

NEW YORK, March 18, 2013 /PRNewswire/ -- Today, Wall Street Source announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Sinovac Biotech Ltd. (NASDAQ: SVA), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) and ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Gilead Sciences, Inc....

2013-03-14 08:28:54

LONDON, March 14, 2013 /PRNewswire/ -- The expiration of patents on several blockbuster drugs has been one of the major trends in the biotechnology sector in the last few years. As major pharmaceutical companies face increasing generic competition following patent expirations, they are likely to see a negative impact on their top-line. Big pharmaceutical companies have been looking to boost their product pipeline to offset the impact of the patent cliff. Another trend that could...

2013-03-06 08:27:07

LONDON, March 6, 2013 /PRNewswire/ -- On Tuesday, the markets retained their bullish mode as indices created yet another life-time high. The markets showed across the board improvement, and the Healthcare sector saw Johnson & Johnson creating a new all time high. The Dow Jones ended its latest session at 14,253.77, up 0.89 percent while NASDAQ was up 1.32 percent to close at 3,224.13. Similarly, S&P closed on a positive note at 1,539.79, up 0.96 percent. Our research...